Wedbush Issues Positive Forecast for Disc Medicine Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Equities researchers at Wedbush upped their FY2026 earnings per share (EPS) estimates for Disc Medicine in a research note issued to investors on Tuesday, January 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($3.96) per share for the year, up from their previous forecast of ($4.19). Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Wedbush also issued estimates for Disc Medicine’s FY2027 earnings at $2.64 EPS.

IRON has been the topic of a number of other research reports. Scotiabank upped their target price on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a research note on Tuesday, November 5th. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Stifel Nicolaus boosted their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a report on Friday. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $88.90.

Disc Medicine Stock Performance

IRON opened at $57.45 on Thursday. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -14.43 and a beta of 0.75. The stock’s 50 day moving average price is $62.62 and its 200-day moving average price is $53.79. Disc Medicine has a one year low of $25.60 and a one year high of $77.60.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 9,158 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $59.64, for a total transaction of $546,183.12. Following the sale, the insider now owns 40,405 shares of the company’s stock, valued at approximately $2,409,754.20. This trade represents a 18.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 85,758 shares of company stock valued at $5,400,990. 4.24% of the stock is currently owned by corporate insiders.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently bought and sold shares of IRON. Amalgamated Bank boosted its position in shares of Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after purchasing an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares in the last quarter. Quest Partners LLC acquired a new stake in shares of Disc Medicine in the 3rd quarter worth $131,000. Quantbot Technologies LP acquired a new stake in shares of Disc Medicine in the 3rd quarter worth $146,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Disc Medicine in the 3rd quarter worth $228,000. Institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.